About US
Contact us
-
Biogen finalizes $900M deal to settle whistleblower's long-running MS kickback suitYears into a whistleblower suit thatalleged illegal kickbacks to physicians, Biogen is now finally able to end thelegal saga just as the troubled drugmaker attends to a corporate restructuring. Bioge2022/9/27
-
Merck, defending its blockbuster Januvia, prevails in high-stakes patent lawsuit against ViatrisMerck & Co., after settling with nearly two dozen drugmakersaiming to launch generics of its blockbuster Type 2 diabetes med Januvia, has successfully parried a Viatris patent assault in court.2022/9/23
-
Novartis dons 'US-first' mindset amid groupwide overhaul, layoffs and generics spinoffDon’t mistake this for former U.S. President Donald Trump talking, but Novartis is taking a “U.S.-first” approach after lagging its Big Pharma peers in the world’s largest pharmaceuticals market.2022/9/23
-
BeiGene keeps its Brukinsa momentum going by winning NICE nod for rare lymphomaMore than a year after scoring an approval for Brukinsain Waldenstrom macroglobulinemia (WM) in the U.S., BeiGene appears poised to launch in that use in the U.K. Tuesday, England’s Natio2022/9/20
-
GSK puts suppliers on the hook as it amps up sustainability crusadeDrugmakers have increasingly put their environmental footprint under a microscope, rolling out power purchase agreements, renewable energy installations and more in a bid to clean up their operations2022/9/20
-
AstraZeneca beats back investor lawsuit over COVID-19 vaccine testing woesAstraZenecastumbled several timesduring the testing and rollout process for its COVID-19 vaccine and never securedan authorization in the U.S. Upset overinvesting losses, some AZ shareholders opted t2022/9/15
-
Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?Among its dozen FDA approvals for a variety of autoimmune disorders, AbbVie’s Humira has plenty of competition in most of its indications. In the debilitating skin condition hidradenitis suppurativa2022/9/15
-
Novartis dodges Gilenya kickback claims—again—after whistleblower lawsuit dismissedFor the second time in as many years, Novartis has dodged claims it paid doctors kickbacks at “sham” speaker programs to boost prescriptions of its multiple sclerosis blockbuster Gilenya.2022/9/13
-
OTC birth control could be on the way from Perrigo, as FDA gathers expert panelAmericans might soon get their hands on a birth control pill, no prescription needed. A joint FDA advisory committee meeting isscheduledfor November 18 to review Perrigo’s application for2022/9/13
-
FDA rejects Alvotech's Humira copycat on manufacturing issuesThe FDArejectedAlvotech’s application to approve its biosimilar copycat drug of AbbVie’s blockbuster immunology asset Humira after an inspection of the company’s Reykjavik, Iceland, manufacturing pla2022/9/9